[8-K] Ikena Oncology, Inc. Reports Material Event

Rhea-AI Filing Summary

Form 8-K highlights for Nine Energy Service (NYSE: NINE) dated 5 Aug 2025:

• Item 2.02 – Results of Operations: The company furnished, but did not file, a press release (Exhibit 99.1) covering Q2-25 results (quarter ended 30 Jun 2025). No financial figures are included in this filing; investors must review the attached exhibit for details. Because the information is “furnished,” it is not subject to Exchange Act Section 18 liability and will not be incorporated by reference unless specifically stated.
• Item 5.02 – Board changes: Director Mark E. Baldwin resigned effective 1 Aug 2025 as previously planned. Jerome (Joey) D. Hall, whose pending appointment had been disclosed earlier, joined the Board on 2 Aug 2025.
• Exhibits: 99.1 – Q2-25 earnings press release; 104 – Cover Page Inline XBRL.

No other material events, transactions or financial statements were reported.

Insights

Corporate Governance Analyst

TL;DR: Routine 8-K; director transition already telegraphed, minimal governance impact.

Baldwin’s planned resignation and Hall’s accession follow prior disclosures, signaling orderly succession rather than turmoil. Absent committee reassignments or activist pressure, governance risk remains unchanged. The furnished earnings press release limits liability exposure, a standard practice. Overall, the filing is neutral for valuation or control considerations.

Equity Research Analyst

TL;DR: Earnings details not in filing; investors must consult Exhibit 99.1.

Because no numerical results are presented, this 8-K alone cannot move the model. Focus shifts to the press release for revenue, EBITDA and guidance updates. Director changes are unlikely to influence operations or capital allocation. Consequently, the filing is informational, not market-moving.

NASDAQ CA false 0001835579 0001835579 2025-08-02 2025-08-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 2, 2025

IMAGENEBIO, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40287		81-1697316
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

12526 High Bluff Drive
Suite 345
San Diego, California		92130
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: 617-901-7098

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		IMA		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 4.01. Changes in Registrant’s Certifying Accountant.

(a) Dismissal of Independent Registered Public Accounting Firm

On August 2, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of ImageneBio, Inc. (formerly Ikena Oncology, Inc.) (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm, with such dismissal to become effective on August 2, 2025 (the “Effective Time”).

EY’s audit reports on the Company’s consolidated financial statements as of and for the years ended December 31, 2024 and 2023 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.

During the Company’s fiscal years ended December 31, 2024 and 2023 and the subsequent interim period through August 2, 2025: (1) there were no “disagreements” (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304) with EY on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of EY, would have caused EY to make reference to the subject matter of such disagreements in connection with its reports on the consolidated financial statements for such periods and (2) there were no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K).

The Company provided EY with a copy of this Current Report on Form 8-K prior to its filing with the SEC and requested that EY furnish the Company with a letter addressed to the SEC stating whether EY agrees with the statements made by the Company in this Current Report on Form 8-K and, if not, stating the respects, if any, in which EY does not agree with such statements. A copy of the letter from EY is filed with this Current Report on Form 8-K as Exhibit 16.1.

(b) Engagement of New Independent Registered Public Accounting Firm

On August 2, 2025, upon the approval of the Audit Committee, PricewaterhouseCoopers LLP (“PwC”) was appointed as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. PwC served as the independent registered public accounting firm of Inmagene Biopharmaceuticals (“Inmagene”) prior to the consummation of the previously reported merger between Inmagene and the Company.

During the Company’s fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through August 2, 2025, neither the Company nor anyone acting on its behalf consulted with PwC regarding: (i) the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided to the Company that PwC concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a “disagreement” within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 or a “reportable event” within the meaning of Item 304(a)(1)(v) of Regulation S-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
16.1*		Letter from Ernst & Young LLP to the SEC dated August 5, 2025.
104		Cover Page Interactive Data File (embedded with the Inline XBRL document).

* Filed herewith

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				IMAGENEBIO, INC.
Date: August 5, 2025				By:		/s/ Kristin Yarema, Ph.D.
						Kristin Yarema, Ph.D.
						Chief Executive Officer

FAQ

What did Nine Energy Service (NINE) disclose in its August 5 2025 Form 8-K?

An earnings press release was furnished and a planned board transition occurred.

Did the 8-K include Q2 2025 financial numbers for NINE?

No, the filing references Exhibit 99.1 for the figures; none are in the body of the report.

Who resigned from Nine Energy Service’s board?

Mark E. Baldwin resigned effective 1 Aug 2025.

Who joined Nine Energy Service’s board on 2 Aug 2025?

Jerome (Joey) D. Hall began serving as a director.

Is the earnings information considered “filed” under the Exchange Act?

No. It is “furnished,” avoiding Section 18 liability unless later incorporated by reference.